Introduction:
We have synthesized a peptide that inhibits the growth of ER+ human breast cancers growing as xenografts in immune-deficient mice, including those that are resistant to tamoxifen (Tam) (1) . This nine amino acid peptide, cAFPep (previously referred to as COP), is derived from alphafetoprotein (AFP) which itself has anti-estrotrophic and anti-breast cancer activity (2) . It has been shown that the peptide does not act like Tam or any other known agent currently used to treat ER+ breast cancer (1 ;2) Although the anti-breast cancer activity of cAFPep and its precursors is welldocumented (1 ;3;4), neither the mechanism of its action nor that of AFP has been fully elucidated (1;2) .
Both cAFPep and its parent molecule AFP would not be expected to freely cross the plasma membrane because of their charge and size. Cell surface receptors have been isolated and characterized for peptide molecules such as oxytocin, vasopressin, and somatostatin and its analogs (5) (6) (7) , and for proteins such as insulin and insulin-like growth factor (8) . The receptors for these molecules act as mediators of signal transduction (5-7;9). Therefore it is reasonable to assume that this peptide interacts with (a) cell surface receptor(s) to mediate its anti-breast cancer activity. While it is possible that the AFP-derived peptide will interact with a receptor for AFP, this remains to be determined. Receptors for AFP have been studied in various undifferentiated cell lines, but have not been completely characterized and no sequence information is available. Isolation and characterization of the receptor for cAFPep will elucidate the first step in the mechanism of anti-oncotic action of this peptide.
During the first year of this training grant, peptides have been synthesized for use in the affinity chromatography (AC) procedure to isolate proteins that have an affinity for the AFP-derived peptides. These peptides have been linked to an affinity column matrix, and the procedure for isolation of breast cancer cells that bind to the peptide has been optimized. A 70 kDa protein was retained by columns coupled to both active and inactive peptides, including peptides with a disrupted pharmacophore, indicating putative non-specificity in the strategy designed to isolate the cAFPep receptor. The second year investigations studied this 70 kDa protein and the isolation strategy in more depth. Multiple proteins with an approximate molecular weight of 70 kDa were seen when affinity column eluents were separated by electrophoresis. One of these proteins which showed qualitative specificity for the AFP-derived peptide was identified as heat shock protein 70 (HSP70). Since HSP70 interacts with the estrogen receptor (ER), investigations during the third year focused on further examining the interactions between HSP70 family members, cAFPep, and the ER in human breast cancer cells.
Body:
Research Accomplishments (Final) A. Isolation of AFPep-specific Cell-Membrane Binding Protein(s) by Affinity Chromatography: 1. Identification of the pharmacophore of the AFP-derivedpeptide. During the first year of this training grant (see May 2003 report), peptides were synthesized for use in an affinity chromatography procedure to isolate cellular proteins from human breast cancer cells which had an affinity for the AFP-derived peptide. These peptides included linear and cyclized AFP-derived peptides, and various control peptides which showed no inhibitory activity in an in vivo assay that measured inhibition of E 2 -dependent growth. Before the cyclized AFP-derived peptide could be coupled to an affinity column it was necessary to determine where the pharmacophore of the peptide was located and to engineer an attachment site into this cyclic peptide to facilitate coupling to the affinity column matrix. Amino acid substitutions were rationally designed and the peptide analogs synthesized and their inhibitory activity determined. Both conservative and non-conservative substitutions of key amino acids which abolished this inhibitory activity indicated where the pharmacophore of the peptide was located. During the second year, this work culminated in a publication in the Journal of Peptide Research (10) . Substitution of a lysine for methionine at a site distal to the pharmacophore in cAFPep resulted in a cyclic peptide with activity comparable to that of the original cyclized molecule and allowed for coupling of this peptide to the affinity column matrix through the free amine group of the side-chain of the lysine. Active (cAFPep and AFPep) and inactive peptides (scrambled peptide and a peptide in which D-val was substituted for L-val) were coupled to affinity columns and the efficiency of coupling evaluated. These peptide affinity columns were utilized to retain proteins from human breast cancer cells which had an affinity for the AFP-derived peptides. 2 . Development of an dffinity chromatography method to isolate cellular binding proteins. During the first year, MCF-7 human breast cancer cells were solublized and passed through the affinity columns.
The conditions for solubilization of these cells were optimized and a 70 kDa protein which was retained by both biologically-active and -inactive peptide columns, but not by a blank column, was isolated using sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). As described in the report from May 2003, the specificity of the binding of this 70 kDa protein for the peptide columns was further evaluated. B. Purification and Characterization of Cell-Membrane Binding Protein(s): 1. Identification of a non-specific cellular binding protein, mortalin, isolated by 2D
electrophoresis. As described in the report for May 2004, to further evaluate the specificity of the retention of the 70 kDa protein by the AFPep column, 2 dimensional (2D) SDS-PAGE was performed. Multiple spots with an approximate molecular weight of 70 kDa were seen using 2D. The most prominent spot isolated was identified by mass spectrometric (MS) analysis as mortalin. This protein was retained by both active and inactive peptides coupled to the affinity columns and was seen in eluents of these columns using both MCF-7 and T47D human breast cancer cells. During the third year, this qualitative specificity was further evaluated using Western blotting which has higher sensitivity and specificity than Coomassie staining of an SDS-PAG. Eluents from active and inactive (control) affinity columns were blotted for inducible HSP70 (HSP72), constitutivelyexpressed HSP70 (HSP73, HSC70), and ERo. As shown in Figure 2 , both inducible and constitutively-expressed forms of HSP70 were retained by the active (AFPep) peptide and by a scrambled peptide which had no biological activity, but substantially less of these proteins were retained by a D-val control column which had the same sequence as that of AFPep, but with a D-val substituted for L-val which renders the peptide inactive. ERca was not retained by any of the peptide affinity columns indicating that the peptide does not bind to ERa (data not shown Modulation of total cellular levels of ERca were also examined by immunoblot. As shown in Figure 3B , treatment of T47D cells with E 2 resulted in an approximately 23% reduction in the total ERa in the cell at 24 hrs. after treatment. Treatment with cAFPep (1 jIM) significantly reduced the total amount of ERa to 57% of the amount in the no-treatment control (p < 0.01). Interestingly, when T47D cells were treated with the combination of cAFPep and E 2 , the total ERa was reduced to 12% (p < 0.001) of that of cells which received medium alone, which is equivalent to only 16% of the ER that remains with treatment with E 2 only and this reduction as compared to the E 2 treatment group is significant (p < 0.01). This suggests that while cAFPep can somewhat reduce the total amount of estrogen receptor in the cell, when combined with E 2 , the reduction is substantially magnified perhaps by downregulation and/or degradation of the ER. The reduction in the total ER suggested that the predominant mechanism of action of the AFP-derived peptide is to down-regulate this receptor. Furthermore, combined treatment of T47D cells with cAFPep and E 2 reduced total progesterone receptor-A ( Figure 2C ). At 24 hours, a slight (10%) increase in PgR protein was seen with treatment with E 2 alone. However, there was a 47% reduction in total PgR in the cell as a result of combined cAFPep and E 2 treatment as compared to the no treatment control and a 50% reduction compared to the E2-only control group. Taken together, these data indicate that cAFPep interferes with ER activity by affecting both the phosphorylation of the ER, total levels of ER, and transcriptional activity of the ER. Further studies to examine the mechanism of reduction of ERct levels are underway. A manuscript is being prepared to report these findings. 3 . Preliminary studies of cAFPep-induced changes in signal transduction. Begun in the second year, phospho-protein screening of lysates of T47D human breast cancer cells cultured on ECMcoated plates and treated with cAFPep and estradiol was performed. As described in the May 2004 report, the phosphorylation status of various intracellular signaling molecules was affected by treatment with cAFPep alone or combined with E 2 . Investigations during the third year followed up on these observations by further probing modulations of numerous signal transduction molecules using immunoblot for total and phosphorylated forms. As shown in Figure 4 , phosphorylation of the kinase-activating site (threonine 108/182) of p38-u was substantially increased at 30 minutes by combined treatment with cAFPep and E 2 . Phosphorylation of the kinase-activating site of SAPK/JNK showed a similar increase in phosphorylation at 30 min. as well. Substantial changes in phosphorylation with combined treatment with cAFPep and E 2 at early time points were also seen for FAK ( Figure 5 ) and Shc ( Figure 6 ). This data suggests that cAFPep interferes with upstream pathways that link E 2 to pro-growth responses and that this may affect the activity of ERa(, and these signal transduction pathways require further study to understand their role in the mechanism of action of cAFPep.
Key Research Accomplishments
Year 1 * Synthesized cAFPep and AFPep peptides with and without linker for use in affinity chromatography. Synthesized peptides for use in specificity (blocking) experiments and analogs for experiments to determine the pharmacophore. Designed and synthesized peptides to be used as controls for the affinity chromatography procedure. The biological activity of all peptides was evaluated using the estrogen-stimulated immature mouse uterine growth assay. Only peptides that had the anticipated biological activity were used in the affinity chromatography experiments. * Peptides were linked to the affinity chromatography matrix using the manufacturer's procedure.
Coupling was evaluated using HPLC, Kaiser test, and amino acid analysis. * MCF-7 and T47D human breast cancer cells were cultured and the confluent monolayers solubilized in a buffer containing a non-ionic detergent. The solubilization buffer components were optimized to reduce degradation and promote stabilization of the binding protein/ligand interaction. The affinity chromatography procedure was further optimized to increase sensitivity and to allow for elution of highly retained proteins by the use of sequential elutions. Proteins retained by the affinity columns were isolated using SDS-PAGE with Coomassie Blue staining to visualize the proteins. * Control peptides, blocking, and peptide elution experiments were performed to evaluate the specificity of the binding proteins isolated. 
Conclusions
The work thus far indicates that this novel human anti-breast cancer peptide interferes with estrogen receptor signaling in human breast cancer cells by decreasing total cellular levels of the estrogen receptor and by interfering with upstream signaling pathways that affect the activity of the estrogen receptor. cAFPep interacts with members of the heat shock protein 70 family of proteins and may interfere with the ERca-HSP complex leading to downregulation of ERct expression and activity.
In addition, the pharmacophore of the peptide has been determined and an in vitro method to measure the activity of the AFP-derived peptides has been developed and validated. Overall, a substantial amount of work has been done to expand the understanding of the mechanism of action of these peptides.
2Taken together, these data suggest a mechanism of action of cAFPep that downregulates the ER by altering the interaction of ER with HSPs. Valine (Val5) can be substituted only with branched-chain amino rations of the structure-activity relationships during acids (isoleucine, leucine or Thr); replacement by D-valine or Ala rational or iterative design and synthesis activities would resulted in loss of biologic activity. Thus, for this site, the bulky be expected to contribute to the understanding of the biobranched side chain is essential. Asparagine (Asn6) is essential for logy and mechanism by which the novel analogs function. activity. Substitution with Gin or aspartic acid (Asp), resulted in A peptide that inhibits the growth of estrogen receptor reduction of biologic activity. Removal of glycine (Gly8) resulted in positive (ER÷) human breast cancers, growing as xenografts a loss of activity but nonconservative substitutions can be made at in immune-deficient, mice has been synthesized (1). this site without a loss of activity indicating that it is not part of the cyclo[EMTOVNOGQI was derived from ct-fetoprotein pharmacophore. Cyclization of the peptide is facilitated by (AFP), a safe, naturally occurring human protein produced addition of Gln9, but this residue does not occur in AFP nor is it during pregnancy, which itself has anti-estrogenic and antinecessary for activity. Gln9 can be replaced with Asn, resulting in a breast cancer activity (2 to-tail' peptide bond, rather than the more usual disulfide Small molecule analogs of proteins, intended for pharmabond, may be advantageous for purposes of shelf life, ceutical or other uses, are usually intended to mimic a retention of structure and activity in vitro, and elimination binding site or active site of the protein, and to provide of dimers, trimers, and higher-order aggregates that can some or all of the function of the parent molecule. After sometimes develop when disulfide-bonded peptides are identifying molecules small enough to be synthetically stored or used in conditions that do not carefully control economical and yet large enough to contain information the redox state. The method of cyclization that was used adequate to provide the desired activity, it is often neceswas developed by Kates et al. (5, 6) and is straightforward sary to optimize the newly developed small molecule in and expedient. terms of several additional parameters, perhaps including Although the anti-breast cancer activity of the linear conformational flexibility, potency, storage stability or and cyclic AFP-derived peptides is well-documented, the stability in vivo, or even other parameters that arise during pharmacophore of the peptide has not been elucidated. the development process, such as targeting to one of several Consequently, we designed and synthesized a number of available receptors. Simultaneous optimization of several of analogs of the linear and cyclized peptides to ascertain these parameters might be achieved through library which atoms are crucial for activity. Because of the relscreening or combinatorial synthesis approaches. Alternatatively few amino acids to be studied and the availability ively, and perhaps especially for situations in which unexof interspecies homology data, a rational, rather than a pected observations contribute importantly to the combinatorial, approach to substitution was utilized. developmental process, rational design approaches offer Conservative and nonconservative substitutions were unique opportunities to optimize the structure and function made for each amino acid as appropriate. Biologic activity of the small molecule protein analog. Furthermore, explodata from the analogs were used to determine the pharmacophore and auxiliary portions of the molecule. ble the growing peptide chain on Fmoc-PAL-PEG-PS resin Simultaneously, comparisons of synthetic outcomes yielbeginning with the C-terminus using Na-protected amino ded information that led to improved approaches for synacids. Activation of the C-terminus of incoming amino thesizing these peptides. Peptides with key substitutions acids was accomplished by treatment with HATU and were produced with high purity, synthetic yield, and bio-DIPEA. Glu9 and the deprotected-terminus. The peptide resin was washed three times with 15 mL of DMF. After each of the three steps, the peptide resin was evaluated for the presence Peptide synthesis of free amine groups using the Kaiser test (7). Subsequent cleavage of the cyclized peptide from the resin using the Peptides were prepared using Fmoc solid-phase synthesis method outlined above resulted in the formation of as previously described (1, 4) . A Pioneer Peptide Synthesis -y-carboxyamido-derivative of Glu9 or Asp9, that is, Gln9 or system (PerSeptive Biosystems, Inc.) was used to assemAsn9, respectively.
Purification of peptides Human breast cancer xenograft assay
Linear peptides were purified using a reverse-phase Cs 8 SepAn in vivo assay for anti-breast cancer activity was perPak cartridge (Waters, Milford, MA, USA). Briefly, a sample formed using the methodology of Bennett et al. (2, 9) . Concontaining peptide of unknown purity was loaded onto a fluent MCF-7 human breast cancer cells growing in pre-washed cartridge and the sample was sequentially monolayer in DMEM without phenol red supplemented eluted with water, 1o, 3o, and 6o% acetonitrile in water.
with 5% bovine calf serum, 2 MM L-glutamine, 1oo IU/mL The fraction containing peptide was then lyophilized. Purpenicillin, ioo ýtg/mL streptomycin, o.1 mm nonessential ity of cyclic peptides was determined after separation of the amino acids, and lo ng/mL bovine insulin were released main component from impurities on a Waters gradient from the flask using trypsin/EDTA (0.25%/o.25%) and 20
semi-preparative reversed-phase liquid chromatographic million cells were pelleted by centrifugation at 20o g and system. The fraction containing the main peak was colthen solidified into a fibrin clot by treatment with lo ltL lected and lyophilized. Peptides used for structure-activity fibrinogen (So mg/mL) and io ltL thrombin (5o units/mL). relationship analysis were purified prior to use in biologic The solid tumor mass was then cut into pieces of approxiassays, and those used in biologic assays were at 95% or mately 1.5 mm diameter. Each tumor segment was greater purity. Peptides were evaluated by amino acid anaimplanted under the kidney capsule of an Institute for lysis and mass spectrometry.
Cancer Homology data o.5 jtg E 2 or vehicle. Twenty-two hours after the second injection, mice were weighed and uteri dissected, trimmed Sequence information was obtained by comparison of the free of mesenteries, and immediately weighed. Uterine homologous region of AFP for the six species studied using weights were normalized to body weight (mg uterine per g sequence data published in the protein data base of the of body weight) to compensate for differences between body National Center for Biotechnology Information provided by weights of littermates. The inhibition of estrogen-stimulathe National Library of Medicine. ted uterine growth was calculated from the average values for each group using the following equation: To determine which residues were essential to the bioacinjected i.p. into immature Swiss mice. One hour later, the mice were tivity of the 8-amino acid, linear peptide (sequence Glutinjected i.p. with 0.5 pig E. or vehicle control. Twenty-two hours after
Met2-Thr3-Pro4-Val5-Asn6-Pro7-Gly8), a series of linear the second injection, mice were killed, the uteri dissected and trimmed free of mesenteries, and weighed. Percent inhibition is calculated as analogs was prepared and evaluated using the immature described in Experimental Procedures. 8-mer Hyp showed inhibition of mouse uterine growth assay. It has been documented that growth of approximately 33% in this assay. ttp < o.oos compared with there is excellent correlation between the uterine growth 8-mer Hyp using Dunnett's multivariate comparison.
assay and the human breast cancer xenograft assay with regard to peptide inhibition of estrogen-stimulated growth Table 1 substantially lower cost. Hence the xenograft assay was
used only for the lead analog. Modifications of peptides Gorilla E M T P V N P G included conservative substitutions for each of the amino Chimpanzee E T T P V N P G acids, deletions of the N-and C-termini, and for some Horse E E S P I N P G amino acids, nonconservative substitutions as well.
Rat
Replacing the highly conserved Glul with Gln or Asn Amino acids that are in bold italic (Residues 1, 4, 6 and 8) are maintained the inhibitory activity of the linear peptide strictly conserved between species and those in italics are semi- (Fig. f) . Substitution of this residue with Lys or Asp reduced conserved. Residues that are in bold (Residues 2, 3 and 7) are not conserved in AFP across those species studied. the activity of the molecule, but did not abolish it. However, the nonconservative substitution of Glul with Ser resulted in an almost complete loss of the inhibitory Thr3 activity of the peptide. Deletion of Glut ablated the inhibAnalogs of the peptide with Thr3Val and Thr3Ala substiitory activity of the molecule.
tutions in the 8-mer peptide were prepared and tested (Table 2 ). Both of these analogs retained the inhibitory Met2 activity of the parent molecule. Substitution of Ser for Thr3 Met2 is not highly conserved across species in AFP resulted in some reduction in inhibitory activity that was (Table t) and can be replaced with Thr (chimpanzee), Glu not statistically significant.
(horse), or Ala (mouse, rat). A linear octapeptide was synthesized with a substitution of Lys for Met2. The peptide Pro4,7 retained full inhibitory activity ( Table 2) . Substitution of
The conservation of Pro4 across species (Table 1) suggested Tyr for Met2 also maintained the inhibitory activity, that this residue was required for the biologic activity of the (Fig. 3) . However, replacement of Val5 with Ala resulted in bold. ++, 25-40% inhibition; +, 12-25% inhibition; -, less than a nearly complete loss of inhibitory activity, and replace-5% inhibition.
ment of Val5 with D-Val completely abrogated the activity of the analog.
Pro4Hyp
Asn6
Pro7Hyp
Peptide analogs were synthesized with conservative substitutions for Asn6 and analyzed for inhibitory activity 8-mer Hyp using the immature mouse uterine growth assay. Replacement of Asn6 with Gln resulted in a significant loss of Pro4Ser, 7Hyp inhibitory activity (Fig. 4) . Substitution with the carboxylic Pro4Hyp, 7 Ser -acid derivative of this residue, Asp, also resulted in a reduction in activity. resulted in a complete loss of biologic activity (Fig. 2) although Ser replaces Pro7 in the AFP of rodents (Table i1 . This is consistent with its conservation across species. (Table I) , was prepared and analyzed using the immature assay after final purification of the peptides. Purity was determined as area percent by HPLC prior to purification.
mouse uterine growth assay ( Table 2 ). This molecule differs
Yield was calculated as amount of peptide recovered after from the AFP-derived linear peptide by substitutions of Lys lyophilization without further purification by HPLC. for Met2, Ser for Asn6, Asp for Pro7, and Arg for Gly8. The synthetic albumin peptide had no inhibitory activity. Table 2 indicated that Lys could be substituted for Figure 5 . Anti-estrotrophic activity of cyclo[EKTOVNOGNj against Met2 without loss of biologic activity, we added either Gin MCF-7 human breast cancer xenografts. There were five to six mice per treatment group. The assay is described in Experimental Procedures. E. was provided by implantation of a silastic tube containing solid E.
lized it. These analogs had inhibitory activity comparable to inserted subcutaneously on day o. Peptide was given once daily at that of the cyclized molecules containing methionine io gg/mouse. Peptide significantly inhibited the estrogen-dependent (Table 3) . However, when the purity of the Lys-containing growth of the tumor. * *P < o.o5.
molecules was evaluated by HPLC, the chromatograms showed the presence of predominantly one peak. The cyclic containing the Met2Lys substitution increased the purity prevented tumor growth over this same time period. of the preparation 2. 4 -fold from 39 to 94% for the Gincontaining analog and fourfold from 24 to 95% for the molecule cyclized using Asn (Table 3) . As a consequence, Discussion the yield of the peptide was increased compared with the cyclic molecule containing Met.
Rationale for investigation of the pharmacophore of AFP-derived The cyclized peptide containing the Met2Lys substitupeptides tion was evaluated for its ability to inhibit the growth of
ER+ human breast cancer cells growing as xenografts under
It had been demonstrated previously that both the linear the kidney capsule in immune-deficient mice. As shown in and cyclic AFP-derived peptides were capable of inhibiting Table 1 was not tested, such, it is logical to assume that the portion of the molecule comparison of the sequences of these peptides served to diametrically across from that Asn to Glu peptide bond, guide our choices for individual amino acid substitutions that is, the 'middle' of the linear peptide, ought to be the when designing analogs; (b) relatively few amino acids pharrnacophore. As a first approximation, the region may be (eight) comprise the minimal sequence necessary for antipostulated to consist of the amino acids between the two estrotrophic activity in APP-derived peptides; and (c) data hydroxy proline residues (Fig. 6 ). generated while determining the minimal sequence and
In the six species evaluated, Val5 is found at this site for optimizing the stability of the peptides (1,4) suggested key all species except equine where the highly conserved le is residues that were required for activity or stability in storfound in place of Val5 ( Table 1) . Consistent with the presage and other residues which could be replaced without loss ence of Ile in equine APP, synthetic analogs with Val5 of biologic activity. The unexpected observation that cyclic substitutions, which retained the hydrophobic and branmolecules provided a wider dose-response curve (i) sugched character, such as le and Leu, retained biologic gested the importance of maintaining the residues necesactivity. However, replacement of Val5 with the smaller, sary for the cyclization process. Thus, the rational approach nonbranched Ala resulted in a significant loss of inhibitory seemed more appropriate for these studies.
activity, suggesting that the branched structure of the side chain at this site was required to maintain the activity of the peptide. To test this hypothesis, Thr was substituted for
Investigation of the pharmacophore Vals, a substitution that conserves the branched nature, but is more hydrophilic than Val. This analog retained antiCyclization of the peptide as previously described (1) conestrotrophic activity suggesting that the branched nature of strains the molecule, causing the peptide to exist largely as the residue at this position is necessary for maximal a planar macrocycle (Pig. 6). The region of the cyclic activity. Interestingly, substitution of Val5 with its molecule near the ring-closing peptide bond (the Asn to Glu enantiomer, n-Val, completely ablated the activity and link) is probably not the pharmacophore, as that peptide suggested that the specific orientation of the Val side chain or of the backbone participates in the binding of the pharmore likely plays a role in maintaining the conformational macophore to its target. stability of the molecule. Asn6 is strictly conserved across those species evaluated Replacing Thr3 with Val, which is more hydrophobic but and even conservative substitutions of Asp or Gln for Asn6 retains the branched nature of the side chain, maintained resulted in a loss of inhibitory activity. This strongly sugthe inhibitory activity of the linear molecule ( Table 2 ). The gests that Asn6 is an essential residue of the active site of nonconservative substitution of Ala also maintained this this molecule, which correlates with what was expected activity. Although there was some loss of activity when Ser based on the interspecies homology, is substituted, this loss was not significant (data not
As shown in Fig. 2 , Hyp can be substituted for either or shown), and considered with the nonconservative Val and both proline residues without a loss of biologic activity Ala substitutions, it can be concluded that the side chain of and it has been demonstrated that Hyp increases the this residue is not required for biologic activity.
storage stability of the AFP-derived peptides (1). An The highly conserved nature of the Gly8 residue suggesinterspecies comparison of Pro4 and Pro7 indicates that ted that this residue may be required ( Table 1) . Deletion of Pro4 is highly conserved, while Pro7 is substituted by Ser Gly8 resulted in a reduction in the biologic activity of the in rodents. To examine the requirement for proline at molecule, but did not abolish it (Table 2) . Furthermore, the these sites, analogs were prepared which replaced Pro4 or nonconservative substitution of Asn for Gly8 resulted in a Pro7 with Ser. Counterintuitive to the interspecies commolecule that retained full activity. This indicates that parisons, the inhibitory activity of the molecule was Gly8 is not part of the active site of this peptide. retained when Pro4 was substituted, but completely Met2 shows no interspecies homology for the six species abolished when Ser replaced Pro7. Thus, the imino acid at evaluated ( Table 1) and synthetic analogs in which Met2 residue 7 is important for conformation of the peptide, and was replaced by either tyrosine or lysine in the linear the backbone atoms at this site are part of the pharmapeptide showed no loss of biologic activity. Taken cophore. The substitution of Ser for Pro4 suggests that together, the data indicate that Glui, Met2, Thr3, and Pro4 is not essential.
Gly8 are not part of the pharmacophore, but it is likely The pharmacophore of the peptide seems to lie between the that they contribute to the conformational stability of the two proline residues and includes the side chains of valine molecule because they can be nonconservatively substiand asparagine, and the backbone atoms contributed by tuted without significant loss of activity. They probably valine, asparagine, and Pro7. This region is highly conserved function to maintain the linear molecule in a conformaamong mammalian species and conservative substitutions tion that is conducive to binding to its receptor. The in this area led to diminution or loss of biologic activity, energy-minimized structure of the 8-amino acid Met-containing peptide has been previously published (4) and this molecule shows the potential to form a horseshoe shaped Amino acids distal to the pharmacophore contribute to the structure. conformational stability of the peptide The substitution of Lys for Met2 was especially advantageous. Molecular modeling (not shown) indicated that the Glui is highly retained across species and this initially 8-amino acid molecule containing this substitution mainsuggested that it may be important to the activity of the tained the horseshoe structure seen previously with the molecule. Conservative substitutions in the linear, 8-amino methionine-containing molecule (4) . Cyclization of the acid peptide of Gln or Asn showed no significant loss of linear peptide containing the Met2Lys substitution (Fig. 6) activity (Fig. 1) . Replacing this residue with Lys, which produced a peptide that was far superior in synthetic outretains a charge at this site, or the highly conservative comes with increased purity ( Table 3) . The optimized anasubstitution of Asp showed some loss of activity, but it was log, cyclo[EKTOVNOGN] not only had anti-uterotrophic not significant. However, replacing Glui with Ser causes a activity (Table 3 ) but also had oncostatic activity in that it loss of biologic activity and deletion of Glui completely inhibited the estrogen-stimulated growth of human breast ablated the inhibitory activity of the molecule. Since subcancer cells growing as xenografts in immune-deficient stitutions in the linear molecule which affect both the mice in a dose dependent manner consistent with that of charge at this site and the size of the side chain resulted in cyclo[EMTOVNOGQ] (Fig. 5) (1) . analogs which retained their biologic activity, it is unlikely
The cyclic peptide is derived from AFP which itself has that Glul is part of the binding site of this peptide. Rather it anti-estrogenic and anti-breast cancer activity. Sonnensch-ein et al. (16) have demonstrated that the growth of an is not trivial. Peptides produced using solid-phase Fmoc estrogen-dependent breast cancer is inhibited in rats bearing synthesis can be produced in high yield and purity in relan AFP-secreting hepatoma. Tumor growth inhibition was atively large amounts, and the AFP-derived peptides have not found when these investigators used an estrogen-indeshown consistent activity over prolonged storage (1) . Genpendent breast cancer. Furthermore, Jacobson et al. (17) and eration of a small, stable, biologically active peptide such as Richardson et al. (18) have shown that elevated levels of described here, and earlier (1, 3, 4) , may suffice for investi-AFP during pregnancy are associated with subsequent gations of the mechanism by which the peptide, and of AFP reduction in the lifetime risk for breast cancer. Jacobson itself, stops the growth of tumor xenografts and exerts its and Janerich (19) have hypothesized that this reduction anti-estrotrophic activity. Further, this peptide may be should be caused by a diminution in estrogen-dependent adequate for preclinical investigations as an oncostatic breast cancers. Bennett et al. (2, 3) have shown that AFP agent, especially if the peptide can be shown to have purified from a human hepatoma culture and then injected appropriate pharmacokinetics and low toxicity. At the very into tumor-bearing immune-deficient mice stopped the least, this cyclic peptide can serve as a model on which to growth of ER+, but not ER-, human breast cancer xenodevelop peptidomimetics. grafts in these mice. Although AFP has demonstrated oncostatic activity (2) , it has limited clinical usefulness. It has
